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Hepatitis C virus (HCV) is the major etiologic agent of blood transfusion–associated and sporadic non-
A non-B hepatitis affecting more than 180 million worldwide. Vaccine development for HCV has been 
difficult and there is no vaccine or effective therapy against this virus. In this paper, we describe the 
development of an experimental plant-derived subunit vaccine against HCV. Our subunit vaccine 
originates from a consensus HCV-HVR1 epitope (R9) that antigenically mimics many natural HVR1 
variants. This HVR1 sequence was cloned into the open reading frame of a plant virus, Alfalfa Mosaic 
Virus (ALMV) coat protein (CP). The chimeric ALMV RNA4 containing sequence-encoding R9 epitope 
was introduced into full-length infectious ALMV-RNA3 that was utilized as an expression vector. The 
recombinant chimeric protein is expressed in transgenic tobacco plants (P12) expressing ALMV RNA1 
and 2. Plant–derived HVR1/ALMV-CP reacted with HVR1 and/or ALMV-CP specific monoclonal 
antibodies and immune sera from individuals infected with HCV. Using plant-virus based transient 
expression to produce this unique chimeric antigen will facilitate the development and production of an 
experimental HCV vaccine. A plant derived recombinant HCV vaccine can potentially reduce expenses 
normally associated with production and delivery of conventional vaccine. 
 






The development of plants and plant viruses for 
expression and delivery of vaccine antigens is a 
particularly promising approach. Plant-derived antigenic 
proteins have delayed or prevented the onset of disease 
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human clinical trials (Amanda et al., 2000). The list of 
plant-derived vaccinogens continues to grow and 
includes viral, bacterial, enteric and non-enteric pathogen 
antigens. In an effort to increase expression levels, 
stability and ease of harvest, synthetic genes have been 
constructed (Mason et al., 1998) and expression has 
been targeted to specific tissues (Brennan et al., 1999). A 
recombinant ALMV was engineered to express two 
rabies virus epitopes (Fleysh et al., 2001). Modelska et 
al. (1998) were the first to detect a mucosal immune  
 





Figure 1. Schematic representation of ALMV-HVR1, an Alfalfa mosaic virus RNA3 (recRNA3) encoding a coat protein (CP) gene fused with 
the sequences encoding chimeric HCV-HVR1 peptide. SP6 and T7, promoters. P3, cell-to-cell movement protein. Arrow indicates the 
subgenomic promoter for RNA4. Amino acid sequences of the chimeric HVR1 peptide is underlined. 
 
 
response after oral induction with a plant-virus-derived 
vaccinogen. This report describes our efforts to develop a 
subunit vaccine candidate for hepatitis C virus (HCV) 
using a modified ALMV to produce recombinant vaccine 
antigens in transgenic tobacco plants. Hepatitis C virus 
(HCV) is the major etiologic agent of blood transfusion–
associated and sporadic non-A non-B hepatitis affecting 
more than 180 million worldwide including nearly 4 million 
in the United States (Cohen, 1999; Di Bisceglie et al., 
1999; Purcell, 1997). Despite a wide array of humoral 
and cell-mediated host immune responses, HCV infection 
leads to chronic disease in about 70% of cases, among 
which a significant proportion eventually develop cirrhosis 
and hepatocellular carcinoma (Alter et al., 1995). Vaccine 
development for HCV has been difficult. Presently, the 
virus cannot be grown in tissue culture and there is no 
vaccine or effective therapy against this virus. Interferon 
treatment (also in combination with ribavirin) is the only 
antiviral therapy available at the moment, but it is 
effective only in 20% to 40% of patients (Fried et al., 
1995; Fried et al., 1998), thus making the development of 
an HCV vaccine a high priority target. It seems possible 
that many of the “evolving” escape epitopes are scattered 
throughout the HCV genome preventing the development 
of an effective anti-viral response (Eckels et al., 1999). In 
fact, HCV displays a high rate of mutation during 
replication and exists in the bloodstream of infected 
patients as quasispecies, (Weiner et al., 1991; Bukh et 
al., 1995) which fluctuates during the course of the 
disease mainly as a result of immune pressure (Bukh et 
al., 1995; Farci et al., 2000). The major target of this 
immune response is the 27 amino acid N-terminal 
segment of the E2 glycoprotein. This protein fragment is 
the most variable region of the whole HCV polyprotein 
(Weiner et al., 1991) and contains a principal 
neutralization determinant (Farci et al., 1996).Recent 
studies described a novel approach to this problem by 
selecting highly cross-reacting “synthetic variants” of 
HCV-HVR1 from a vast repertoire of HVR1 surrogates as 
fusion to the major coat protein of bacteriophage M13 
(Puntoriero et al., 19980). When used in the form of 
multiple antigenic peptides (MAP) (Pessi et al., 1990), the 
selected HVR1 peptide mimics (mimotopes) induced 
antibodies in mice and rabbits that recognizeda large 
number of HVR1 variants from natural isolates 
(Puntoriero et al., 1998). HCV HVR1 (R9)/cholera toxin B 
subuinte (CTB) protein expressed by recombinant 
tobacco mosaic virus (TMV) reacted with HVR1-spesific 
monoclonal antibodies as well as with sera from HCV 
infected patients (Nemchinov et al., 2000). HVR1 epitope 
(R9) expressed protein in plant using Cucumber Mosaic 
Virus (CMV) display the epitope demonstrated significant 
immunoreactivity to HCV serum from infected patients 
(Natilla et al., 2004). In our research, we chose a vaccine 
development approach that is predicted to be effective 
against extremely high antigen variability. This HVR1 
sequence was cloned into the open reading frame of 
ALMV CP (Yusibov et al., 1995) in an intermediate of 
vector that contained the cDNA of ALMV RNA4. This 
chimeric sequence then was introduced into a full-length 
ALMV-RNA3 vector that was used to produce in vitro 
transcripts to inoculate P12 tobacco plants. This 
recombinant chimeric protein is expressed in transgenic 
tobacco plants (P12) expressing ALMV- RNA1 and 2 
(Thole et al., 2001). 
 
 
MATERIALS AND METHODS 
 
Plasmid DNA construction  
 
HVR1 consensus sequences coding 27 amino acids (R9 epitope) 
were synthesized using polymerase chain reaction. Two 
oligonucleotides were designed with 12 overlapping nucleotides 
and served as a template for each other. Nucleotide sequence for 
the upstream (5`-cgg ctc gag atg tcc caa acc acc gtg gtc ggc gga tct 
caa tct cat acc gtg cgt ggc ctc-3`) with XhoI engineered restriction 
site (underlined) and the downstream (5` gcg gtc gac cta ttt tga gaa 
gcg cca gga gag aag aga gat gtg agg cca cgc ac-3`) with SalI 
engineered restriction site (underlined). The resulting PCR product 
was cloned into pGEM-T-Easy vector (Promega, Madison, WI). The 
HCV-HVR1 PCR-amplified product was digested XhoI and SalI, and 
then cloned into XhoI site pSP∆AUG (Yusibov et al, 1995). After 
sequence confirmation, the chimeric ALMV RNA4 containing 
sequence encoding R9 epitope was introduced into full-length 
RNA3 cDNA construct that was utilized as the expression vector 
(Figure 1). 




1         ATGTCCCAAACCACCGTGGTCGGCGGATCTCAATCTCATACCGTGCGTGGCCTCACATCT 
 
61        CTCTTCTCTCCTGGCGCTTCTCAAAATAGGTCGAGTTCTTCACAAAAGAAAGCTGGTGGG 
 
121       AAAGCTGGTAAACCTACTAAACGTTCTCAGAACTATGCTGCCTTACGCAAAGCTCAACTG 
 
181       CCGAAGCCTCCGGCGTTGAAAGTCCCGGTTGTAAAACCGACGAATACTATACTGCCACAG 
 
241       ACGGGCTGCGTGTGGCAAAGCCTCGGGACCCCTCTGAGTCTGAGCTCTTTTAATGGGCTC 
 
301       GGCGTGAGATTCCTCTACAGTTTTCTGAAGGATTTCGCGGGACCTCGGATCCTCGAAGAG 
 
361       GATCTGATTTACAGGATGGTGTTTTCCATAACACCGTCCTATGCCGGCACCTTTTGTCTC 
 
421       ACTGATGACGTGACGACTGAGGATGGTAGGGCCGTTGCGCATGGTAATCCCATGCAAGAA 
 
481       TTTCCTCATGGCGCGTTTCACGCTAATGAGAAGTTCGGGTTTGAGTTGGTCTTCACAGCT 
 
541       CCTACCCATGCGGGAATGCAAAACCAAAATTTCAAGCATTCCTATGCCGTAGCCCTCTGT 
 
601       CTGGACTTCGACGCGCAGCCTGAGGGATCTAAAAATCCCTCATACCGATTCAACGAAGTT 
 
661       TGGGTCGAGAGAAAGGCGTTCCCGCGAGCAGGGCCCCTCCGCAGTTTGATTACTGTGGGG 
 
721       CTGCTCGACGAAGCTGACGATCTTGATCGTCATTGATG 
     
B 
1 M  S  Q  T  T  V  V  G  G  S  Q  S  H  T  V  R  G  L  T  S 
 
21         L  F  S  P  G  A  S  Q  N  R S  S  S  S  Q  K  K  A  G  G 
 
41         K  A  G  K  P  T  K  R  S  Q  N  Y  A  A  L  R  K  A  Q  L 
 
61         P  K  P  P  A  L  K  V  P  V  V  K  P  T  N  T  I  L  P  Q 
 
81         T  G  C  V  W  Q  S  L  G  T  P  L  S  L  S  S  F  N  G  L 
 
101        G  V  R  F  L  Y  S  F  L  K  D  F  A  G  P  R  I  L  E  E 
 
121        D  L  I  Y  R  M  V  F  S  I  T  P  S  Y  A  G  T  F  C  L 
 
141        T  D  D  V  T  T  E  D  G  R  A  V  A  H  G  N  P  M  Q  E 
 
161        F  P  H  G  A  F  H  A  N  E  K  F  G  F  E  L  V  F  T  A 
 
181        P  T  H  A  G  M  Q  N  Q  N  F  K  H  S  Y  A  V  A  L  C 
 
201        L  D  F  D  A  Q  P  E  G  S  K  N  P  S  Y  R  F  N  E  V 
 
221        W  V  E  R  K  A  F  P  R  A  G  P  L  R  S  L  I  T  V  G 
 
241        L  L  D  E  A  D  D  L  D  R  H  * 
 
 
Figure 2.  A Nucleotide sequence of HVR1/ALMV CP chimeric gene. B Translated amino acid sequence of the 




In vitro transcription and plant inoculation 
 
Plasmid DNA corresponding to recombinant RNA3 of ALMV-HVR1 
was linearized with SmaI at the 3` end of the cDNA sequence of the 
v i ra l  cons t ruc t  and  pur i f i ed  us ing  bu f fe red-sa tu ra ted 
phenol/chloroform/isoamyl alcohol (25:24:1). One µg of linearized 
DNA was used to produce in vitro transcripts using T7 Cap Scribe 





Transgenic P12 tobacco plants were inoculated with a mixture of in 
vitro synthesized transcripts of recombinant ALMV-HVR1 RNA3 
and subgenomic RNA4.  
 
 
Reverse transcription-polymerase chain reaction (RT-PCR) 
assay 
 
Total RNA was extracted from systemically ALMV-HVR1-infected 
(20 days post inoculation) and uninfected leaves by RNeasy plant 
kit according to the manufacturer recommendation (Qiagen, 
Valencia, CA). The purified RNA was eluted in water and kept at -
70ºC for conventional RT-PCR. Five µg were reverse transcribed in 
20 µl reaction mixture containing 100 µM of complementary primer 
specific for ALMV CP (5`-cgcggatccgaggtcccgcgaaatcct-3`), 5 µl of 
first stranded buffer and 200 units of M-MLV reverse transcriptase 
enzyme (Life Technologies, Gaithersburg, MD). Five µl of the 
cDNA, 5 µM of forward (5`-atgtcccaaaccaccgtggtcggcg-3`) and 
complimentary primers were mixed with PCR reaction mixture 
containing 2.5 units of Ampli Taq enzyme.   The PCR   parameters: 
94˚C for 2 min one cycle, 94˚C for 30 sec (denaturing) 55˚C for 30 
sec, (annealing) and 72˚C for 45 sec (extension) for 35 cycles, with 
final extension 72˚C for 10 min.   
 
 
Western blot  analysis for the recombinant protein 
 
One hundred milligram of ALMV-HVR1 infected leaves were placed 
in Eppendorf tubes and homogenized in 1X PBS containing 1% 
plant protease inhibitor cocktail (sigma), and boiled for 10 min in 2X 
loading buffer (2% sodium dodecyl sulfate [SDS], 10% glycerol, 5% 
β-mercaptoethanol, 0.01% bromophenol blue, and 50 mM Tris-HCl, 
pH 6.8). The mixtures containing ALMV-HVR1were separated on 
12% SDS-polyacrylamide gels and transferred onto a nitrocellulose 
membrane. The membrane was blocked with 5% dry non-fat milk in 
1X PBS buffer, and then incubated in diluted monoclonal antibodies 
(1:10,000) against ALMV CP conjugated with horseradish 
peroxidase (Agdia, Elkhart, IN) for 1 h. The membrane was washed 
6X with PBST 5 min each and ALMV CP signal was detected by 
super signal west pico chemiluminescent substrate (Pierce, 
Rockford, IL). Recombinant ALMV CP containing chimeric R9 
HVR1 mimotope, in addition, was detected with ALP213 
monoclonal antibodies for HVR1 that recognizes epitope 
GAARSTLQLAGLFQPGAKQN, a 390-409 ALP213 was generously 
provided by Dr. Jane McKeating of University of Reading and Dr. 
Arvin Patel of MRC, Glasgow, UK. Mabs were used at 1:5,000 
dilution and sera at 1:10,000 dilutions. Infected human serum was 
also used for the detection of HVR1 mimotope.  
 
 
ELISA assay for detection of HVR1 epitope 
 
ELISA plates were coated with 100 µl per well of anti-ALMV CP 
monoclonal antibodies (1:5,000) dilution in carbonate buffer (50 mM 
Na2CO3, pH 9.0) for 2 h at 37˚C, then blocked with 1X I block (1X 
PBS, 0.5% I-block, 0.1 % Tween) at room temperature for 1 h. 
Plates were incubated overnight with the plant samples at 4˚C, 
followed by incubation with anti-ALMV CP Mabs, or anti-HVR1 Mab  
 (ALP213), or infected human serum, or normal human serum at 
37˚C for 2 h. All washing steps between incubations were 
performed with 1X PBS-Tween buffer. The plates were incubated at 
room temperature for 1 h with anti-mouse or anti-human IgG-HRP 
conjugate, and then freshly prepared horseradish peroxidase 
substrate was added to the wells. The plate was covered with foil 
and incubated at room temperature for 30 min. The reaction was 
stopped by the addition of 50 µl of l.5 M sulphuric acid to each well 
and the absorbance was measured at 492 nm.  
 






Figure 3. Shows the stunting of P12 plants infected with 
recombinant ALMV. P1; P12 plant infected with recombinant ALMV. 





Construct engineering and nucleotide sequencing  
 
We chose cross-reactive HVR1 mimotope R9, which 
antigenically mimics a large number of natural HCV-
HVR1 variants and induces a broadly cross-reactianti-
HVR1 response (Puntoriero et al., 1998). The sequence 
encoding the 27 amino acid-long HVR1 mimotope 
(engineered to contain XhoI at 5` and SalI at 3` ends) 
was fused to the amino-terminus of the ALMV CP gene in 
pSP∆AUG using an XhoI site. DNA sequencing 
confirmed the ligation of HVR1 mimotope, in-frame, to the 
ALMV CP gene in pSP∆AUG vector.  Translation of 
recombinant ALMV CP in recRNA3 starts from the AUG 
codon introduced at the 5` end of the DNA sequence 
encoding the chimeric HVR1 mimotope after introduction 
of the chimeric cDNA sequence for ALMV RNA4 into the 
full-length infectious RNA3. The recombinant RNA3 
carrying the HVR1 sequence was placed under control of 
the SP6 promoter. The assumption was that HVR1/ALMV 
CP subgenomic message transcribed from recombinant 
viral RNA will be translated into ALMV coat protein 
particles displaying the HVR1 epitope on their surface. 
 
 
Infectivity and stability of recombinant ALMV 
 
In-vitro synthesized capped RNA transcripts of 
recombinant ALMV RNA3 and subgenomic RNA4 were 
used to inoculate the three upper leaves of transgenic 
tobacco plants (P12) that were at the four-leaf stage. To 
assess the stability of recombinant virus, we prepared 
extracts from systemically infected leaves of plants at 20 
days post inoculation (dpi) and used it as inoculum for 
new P12 plants. Infection with the recombinant virus 
resulted in mild mosaic symptoms in the upper 
uninoculated leaves and stunting of plant growth is 
similar, but not as severe, to that observed in the wild-
type ALMV (Figure 3).  






    
Figure 4. RT-PCR with total RNA from P12 transgenic plants 
inoculated with hybrid ALMV vector. M; 100 bp DNA marker. L1& 
L2; P12 plants inoculated with rec. RNA3. H; healthy plant control. 






Figure 5. Shows the autorediographic from the Western Blot 
analysis for the recombinant ALMV coat protein Probed with anti 
ALMV antibodies. 1 to 8 Different Plants infected with recombinant 






Figure 6. Shows the autoradiographic from the Western Blot 
analysis for the recombinant ALMV coat protein probed with anti 
HVR1 monoclonal antibodies. 1: Uninfected plant; 2, 3, 6, 7: 
different plants infected with recombinant ALMV; 4,5: different 




Amplification of HVR1 epitope by RTPCR  
 
To confirm that the ALMV RNA3 from infected plants 
indeed carried the engineered epitope, we performed an 
RT-PCR assay in total RNA from infected P12 plant. The 







                
Figure 7. Shows the autoradiographic from the Western Blot 
analysis for the recombinant protein probed with HCV infected 
human serum. 1: Uninfected plant; 2, 3, 6, 7: different plants 
infected with recombinant ALMV. 4, 5: different plants infected with 






Figure 8. Shows the autoradiographic from the Western Blot analysis of 
total protein examined infected normal human serum: 1 Uninfected 
plant; 2, 3, 6, 7 different plants infected with recombinant ALMV; 4,5: 
plants infected with wild type ALMV. 
 
 
obtained from several P12 plants infected with the 
recombinant virus (Figure 4 lanes 1 and 2). No PCR 
amplification obtained from P12 plants infected with wiled 




Accumulation of recombinant ALMV in infected 
plants and western Blotting 
 
Western blot analysis was performed for tissue samples 
from locally and systemically infected leaves collected at 
7, 15 and 20 dpi. Only samples collected at 15 and 20 dpi 
revealed a band of the size expected for the ALMV CP 
(24.0 kDa) with different band intensities but not in 
samples collected at 7 dpi or samples from healthy 
plants, as detected by reactivity with ALMV CP-specific 
antibodies. Similar analysis of tissue samples from 
systemically infected leaves collected at 20 dpi 
demonstrated expression of recombinant protein, with 
antibodies specific for ALMV CP (Figure 5) and 
monoclonal antibodies specific for HCV (Figure 6) and 
human serum infected with HCV (Figure 7) revealing the 
expected size protein (~31 KD) but not with normal 








Figure 9. Shows the ELISA plate coated with anti ALMV CP 
antibodies and propped with monoclonal anti-HVR1 antibodies              
(rows B and C)    or HCV  infected  human  sera  [rows D and E]  or 
normal sera (rows F and G). P1, P2 and P3 are plant samples 
infected with recombinant ALMV. P4, plant sample infected with 




only with ALMV CP-specific antibodies and not with 
monoclonal antibodies specific for HCV or Infected 
human serum.  
 
 
Elisa tests  
 
ELISA tests using anti-ALMV CP monoclonal antibodies 
clearly demonstrated that transgenic tobacco plants 
(P12) infected with recombinant ALMV RNA3 and 
subgenomic RNA4 transcripts produce the chimeric 
ALMV coat protein (Figure 9). To prove that the ALMV 
coat protein carried the HVR1 peptide fused to its 
surface; we performed an ELISA assay using anti-ALMV 
CP monoclonal antibodies as primary antibodies to 
capture the ALMV-CP/HVR1 fusion protein on the ELISA 
plates and ALP 213 anti-HVR1 monoclonal antibodies or 
infected human serum to specifically detect the HVR1 
epitope on the captured chimeric protein. As shown in 
Figure 9, only plants infected with the recombinant ALMV 
were positive indicating that the HVR1 epitope expressed 
was associated with the ALMV CP.HCV infected human 
sera [rows D and E] or normal sera (rows F and G). P1, 
P2 and P3 are plant samples infected with recombinant 
ALMV. P4, plant sample infected with wild type ALMV. 





Plants have been actively targeted for the production of 
medically important proteins, including vaccine antigens 
and monoclonal antibodies (Hiatt et al., 1989). A variety 
of antigens have been expressed in transgenic plants; 
including hepatitis B surface antigen (Mason et al., 1992), 
Escherichia coli heat-labile enterotoxin (Haq et al., 1995),  




rabies virus glycoprotein (McGarvey et al., 1995), and 
Norwalk virus capsid protein (Mason et al., 1996). In 
addition to transgenic plants, alternative approach to 
express high levels of foreign proteins uses viruses that 
infect plants (Dalsgaard et al., 1997; Hamamoto et al., 
1993; Modelska et al., 1998; Porta et al., 1994; Turpen et 
al., 1995; Usha et al., 1993; Yusibov et al., 1997; 
Nemchinov et al., 2000; Natilla et al., 2004).  An 
important aspect of using plant viruses as production 
tools is screening and establishing appropriate host 
species for manufacturing large quantities of 
polypeptides. The present study suggests the usefulness 
of plants as a vehicle for producing anti-HCV vaccine 
utilizing an ALMV-based expression vector. 
Plant-synthesized recombinant ALMV CP/HVR1 protein 
appears to be in the biologically active configuration and 
immunoreactive for its ALMV CP and HVR1 epitopes. 
The ALMV CP-displayed HVR1 antigenic determinant 
cross-reacted with different serum samples derived from 
HCV-infected patients. This is a direct confirmation of 
immunological similarity between the R9 HVR1 
“mimotope” expressed in plants and the natural HVR1 
variants. Thus, if HVR1 indeed contains a principal 
neutralization epitope for HCV, a plant-produced, purified 
HVR1 surrogate antigen will be able to induce cross-
neutralizing antibodies against most HCV quasispecies.  
Monoclonal antibodies specific for aa 384-391 within 
HVR1 interfere with the interaction of HCV E2 
glycoprotein with CD81 (Flint et al., 1999), which is the 
putative HCV cellular receptor (Pileri et al., 1998) 
suggesting a functional role of HVR1 in viral attachment 
and entry into the host cells. Hence, HVR1 may be a 
prominent target for host neutralizing activity. The latter 
observation has been postulated and experimentally 
shown to be true (Shimizu et al., 1996; Zibert et al., 1995; 
Zibert et al., 1997). An experimental vaccine has also 
been examined in chimpanzees (Esumi et al., 1999). If 
the capacity of HCV to consistently escape immune 
recognition is indeed related to HVR1 heterogeneity, an 
HVR1-consensus approach developed by Puntoriero et 
al. (1998) is an attractive strategy for obtaining cross-
neutralizing HCV antibodies.  
The cross-reactivity of plant produced ALMV CP-
displayed HVR1 epitope with different HCV infected sera 
could potentially make this chimeric protein a simple and 
inexpensive diagnostic tool for the virus. 
The large scale production of biopharmaceuticals in 
plants is clearly a matter of the near future (Cunningham 
et al., 1998; Hammond et al., 1999). The recombinant 
ALMV used in this study does not represent a biohazard 
and the “foreign sequence” will not remain in the 
environment because of subsequent reversion of the 
recombinant virus to the wild type (Hammond et al., 
1999). The use of transgenic P12 plants expressing 
RNA1 and RNA2 components of ALMV minimize the risk 
of recombinant ALMV virus infecting or being transmitted 
to other susceptible plants (other than P12 plants) in the  




environment because the recombinant ALMV developed 
in this study contains only the recombinant RNA3 and 
sub-genomic RNA4 but not RNA1 or RNA2. This is an 
added attractive feature of this system.  
We have demonstrated that sufficient quantities of 
recombinant virus containing chimeric HCV peptide can 
be recovered from systemically infected leaves at 20 dpi. 
In addition, HVR1 consensus sequence fused to ALMV 
CP can be recovered in a very cost-effective manner 
utilizing standard virus isolation procedure. Introduction of 
foreign sequences, however, has resulted in some 
attenuation of virus accumulation and severity of 
symptoms. Reduction of symptom severity, however, 
results in the accumulation of larger amounts of source 
material (e.g. leaves and roots). Thus, considering the 
quantities of virus we are able to recover, utilizing a very 
economical procedure (virus isolation), and this approach 
has great potential for producing foreign sequences in 
plants in a safe, time- and cost-efficient manner. 
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